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Abstract: Oxazolidinones are antibiotics that inhibit protein synthesis by binding the 50S ribosomal 
subunit. Recently, numerous worldwide researches focused on their properties and possible 
involvement in cancer therapy have been conducted. Here, we evaluated in vitro the 
antiproliferative activity of some 5-(carbamoylmethylene)-oxazolidin-2-ones on MCF-7 and HeLa 
cells. The tested compounds displayed a wide range of cytotoxicity on these cancer cell lines, 
measured by MTT assay, exhibiting no cytotoxicity on non-tumorigenic MCF-10A cells. Among the 
nine tested derivatives, four displayed a good anticancer potential. Remarkably, OI compound 
showed IC50 values of 17.66 and 31.10 µM for MCF-7 and HeLa cancer cells, respectively. 
Furthermore, we assessed OI effect on the cell cycle by FACS analysis, highlighting a G1 phase 
arrest after 72 h, supported by a low expression level of Cyclin D1 protein. Moreover, mitochondrial 
membrane potential was reduced after OI treatment driven by high levels of ROS. These findings 
demonstrate that OI treatment can inhibit MCF-7 and HeLa cell proliferation and induce apoptosis 
by caspase-9 activation and cytochrome c release in the cytosol. Hence, 5-(carbamoylmethylene)-
oxazolidin-2-ones have a promising anticancer activity, in particular, OI derivative could represent 
a good candidate for in vivo further studies and potential clinical use. 
Keywords: oxazolidinones; apoptosis; mitochondria; ROS; anticancer compounds 
 
1. Introduction 
Cancer is one of the main causes of morbidity and mortality in the world. In 2015, it was 
responsible for 8.8 million deaths, and the number of new cases is predicted to increase by about 70% 
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over the next 20 years [1]. Several of the most widespread cancer types, such as cervical, breast, oral, 
and colorectal tumors have high cure rates when early diagnosed and treated. Surgery and radiation 
represent useful treatments, but their use is limited by the ability of many solid tumors to spread to 
different parts of the body. Furthermore, metastatic process frequently occurs before the primary 
cancer is diagnosed [2]. 
Consequently, the research aimed at discovering new useful chemotherapeutic agents is still 
very important. In this regard, various Food and Drug Administration (FDA)-approved antibiotics, 
used to treat bacterial infections, have arisen as new promising anticancer drugs; in particular, some 
of them were proved to target mitochondria in Cancer Stem-like Cells (CSCs), selectively inducing 
cancer cell death [3–5]. This event could be understood considering that mitochondria originally 
evolved from endosymbiotic bacteria, so it is likely that an inhibition of the mitochondrial function 
could trigger cell death [3]. 
On this basis, oxazolidinones might represent an interesting class of synthetic compounds useful 
in cancer treatment. In fact, they are known to be potent antibacterial agents, used against multidrug-
resistant gram-positive bacteria [4]. These synthetic compounds bind to the ribosomal 50S subunit by 
inhibiting the initiation phase of bacterial translation [5]. Linezolid was the first member of this class 
to be approved in 2000 by FDA and clinically used for the treatment of gram-positive infections [6], 
especially those caused by Methicillin-resistant Staphylococcus aureus and Vancomycin-resistant 
Enterococcus faecalis [7]. Since Linezolid-resistant bacteria began to appear, several structural 
modifications were performed in order to synthesize and test new molecules [7]. Resistance cases 
were associated with 23S rRNA mutations during treatment [8] or with the presence of the resistance 
genes cfr or optrA [9]. 
During the last decades, many studies highlighted the ability of oxazolidinones to exert 
multifaceted biological activities, since they are able to interfere with factor Xa [10] aldose reductase 
[11], HIV [12], metabotropic [13], and glutamate receptor [14]. Furthermore, some derivatives 
exhibited antidiabetic [15], [16], anticonvulsant [17], and anticancer activity [18], [19],[20], [21]. 
Moreover, further literature data indicate that different oxazolidinone derivatives are endowed with 
promising antineoplastic activity, in particular by acting as partial agonists of peroxisome 
proliferator-activated receptor-gamma (PPAR-γ) [22]. Other oxazolidinones, derived from linezolid 
3, inhibit cell proliferation inducing apoptosis by caspase-3 and -9 activation in DU145 prostate cancer 
cells [18], while different 2-thioxo-oxazolidin-4-one derivatives exhibited anticancer activity on 
hematopoietic cancer cells, and significantly increased the expression of genes involved in 
inflammation and apoptosis in acute leukemia cells [23]. Very recently, dehydroabietic acid 
oxazolidinone hybrids have shown to exert a promising antiproliferative activity on several human 
cancer cell lines, and a particular compound is able to induce apoptosis by causing an arrest of the 
cell cycle in the G1 phase [24]. Thus, development and evaluation of new oxazolidinones as possible 
anticancer agents is a very interesting ongoing research topic [23], [25], [26]. 
In the present work, we evaluated the in vitro anticancer properties of some particular 
oxazolidinone derivatives, which are 5-(carbamoylmethylene)-oxazolidin-2-ones (OA-OI) shown in 
Scheme 1, against estrogen receptor-positive (ER+) breast cancer (MCF-7) and uterin cervix 
adenocarcinoma (HeLa) cell lines. These compounds were recently synthesized in our laboratories 
by water-promoted, palladium-catalyzed oxidative carbonylation of α,α-dialkyl-substituted 
propargylamines [27], [28], and have not hitherto been tested for their anti-proliferative potential. We 
have found that some of these derivatives possess a promising anti-proliferative activity, and that a 
particular compound ((E)-2-(3-benzyl-4,4-dimethyl-2-oxooxazolidin-5-ylidene)-N,N-
diethylacetamide, (OI) is able to induce apoptosis through the mitochondrial intrinsic pathway, 
increasing ROS production and affecting mitochondrial functions. 
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Scheme 1. The in vitro anticancer properties of 5-(carbamoylmethylene)-oxazolidin-2-ones (OA-OI). 
2. Experimental Section 
2.1. Synthesis of oxazolidinones OA-OI 
5-(Carbamoylmethylene)-oxazolidin-2-ones OA-OI were synthesized by water-promoted, 
palladium-catalyzed oxidative carbonylation of α,α-dialkyl-substituted propargylamines carried out 
in the presence of dialkylamines as external nucleophiles, as we already reported [27,28]. Briefly, a 35 
mL stainless steel autoclave was charged with PdI2 (8.3 mg, 0.023 mmol), KI (38.3 mg, 0.23 mmol), 
the propargylic amine derivative (1.15 mmol), and the dialkylamine (5.75 mmol) dissolved in the 
ionic liquid 1-ethyl-3-methylimidazolium ethyl sulfate (EmimEtSO4) (2.3 mL). Water (103.5 µL, 5.75 
mmol) was then added, and the autoclave was sealed and pressurized at 20 atm (16 atm CO and 4 
atm air). After stirring at 100 °C for 24 h, the autoclave was cooled and degassed. The mixture was 
then extracted with Et2O (6 × 4 mL), the collected ethereal phases were concentrated under vacuo, 
and the products purified by column chromatography on neutral alumina using hexane:AcOEt from 
95:5 to 6:4 as the eluent. 
2.2. Cell Cultures 
Human uterin cervix adenocarcinoma (HeLa), human breast cancer ER+ (MCF-7), and MCF-10A 
human mammary epithelial cells were all purchased from American Type Culture Collection (ATCC, 
Manassas, VA, USA). 
HeLa and MCF-7 cells were maintained in DMEM-F12 medium (Sigma-Aldrich, Milan, Italy)  
containing 10% fetal bovine serum (FBS, Sigma-Aldrich, Milan, Italy), 2 mM L-glutamine (Sigma-
Aldrich, Milan, Italy) and 1% penicillin/streptomycin (Sigma-Aldrich, Milan, Italy), as previously 
reported [29]. MCF-10A cells were cultured in DMEM-F12 supplemented with 10% horse serum (HS, 
Sigma-Aldrich, Milan, Italy) [30], 2 mM L-glutamine, 1% penicillin/streptomycin, 0.5 mg/mL 
hydrocortisone (Sigma-Aldrich, Milan, Italy), 20 ng/mL human epidermal growth factor (hEGF, 
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Sigma-Aldrich, Milan, Italy), and 0.1 mg/mL cholera enterotoxin (Sigma-Aldrich, Milan, Italy). All 
the tested cell lines were grown at 37 °C in 5% CO2 in a humidified atmosphere and periodically 
screened for possible contamination. All the tested compounds were dissolved in dimethylsulfoxide 
(DMSO, Sigma-Aldrich, Milan, Italy), and opportunely diluted in DMEM/F12 medium 
supplemented with 2% FBS in order to achieve working concentrations. 
2.3. Cell Viability Assay 
Cell viability was assessed by using 3-(4,5-dimethylthiazol-2-y1)-2,5-diphenyltetrazolium 
bromide (MTT) assay (Sigma-Aldrich, Milan, Italy), as already reported [31]. In brief, MCF-7 and 
HeLa cells (2 × 104 cells/well) were seeded in a 48-well plate and grown in complete medium 
overnight, then they were switched into DMEM-F12 supplemented with 2% FBS and treated with 
increasing concentrations (1, 10, 50, 75, and 100 µM) of different oxazolidin-2-ones derivatives (OA-
OI) or doxorubicin for 72 h. Untreated cells were added with the vehicle (DMSO) and used as a 
control. After treatment, fresh MTT reagent (used at a final concentration of 0.5 mg/mL) was added, 
prolonging incubation for 2 h according to the manufacturer’s protocol. Absorbance at 570 nm was 
measured in each well, including controls, and every experiment was carried out in triplicate. 
For each sample, mean absorbance was expressed as a percentage of the control and plotted vs. 
drug concentration, in order to determine the IC50 value (i.e., drug concentration able to decrease 
cell viability by 50% with respect to the control) for each cell line [32], generating a sigmoidal dose–
response curve by the use of GraphPad Prism 7 software (GraphPad Inc., San Diego, CA, USA). Mean 
values and standard deviations (SD) of three independent experiments carried out in triplicate were 
reported. 
In order to examine the cytotoxic effects of the compound OI, cell proliferation assay was 
assessed in the presence of N-acetylcysteine (NAC, Sigma-Aldrich, Milan, Italy), a reactive oxygen 
species (ROS) scavenger, as described in [33]. Briefly, MCF-7 and HeLa cells treated with 15 and 30 
µM OI, respectively, were incubated with or without 3 mM NAC. After 72 h, cell viability was 
evaluated by MTT assay. 
2.4. Cell Cycle Analysis 
In order to assess cell cycle analysis, MCF-7 and HeLa cells were seeded in 6-well plates, at a 
density of 2.5 × 105 cells/well, then they were added to DMSO or treated using 15 and 30 µM OI, 
respectively, for 24 h. MCF-10A were seeded as described before, then they were added to DMSO or 
treated using 30 µM OI, the highest concentration used for cancer cells, for 24 h. Next, cells were 
harvested by trypsinization, rinsed twice with cold PBS, and pelleted by centrifugation at 1500 rpm 
for 5 min. Pellets were re-suspended in 70% ice-cold ethanol for 30 min at 4 °C to perform cell fixation. 
Then, samples were rinsed twice with PBS and stained using a solution containing 3.8 mM sodium 
citrate (Sigma-Aldrich, Milan, Italy), 100 µg/mL RNAse (Sigma-Aldrich, Milan, Italy) , 50 µg/mL 
propidium iodide (PI, Sigma-Aldrich, Milan, Italy), and 0.1% Igepal (Sigma-Aldrich, Milan, Italy) in 
PBS for 1 h at 37 °C. Subsequent cytofluorimetric analysis [34] was achieved by BD FACSJazzTM Cell 
Sorter (Becton Dickinson, Franklin Lakes, NJ, USA). 
2.5. Mitochondria Extraction 
Both MCF-7 and HeLa cells were cultured in 100 mm dishes (1 × 107cells/dish), added with the 
vehicle alone (DMSO) or treated for 24 h with 15 and 30 µM OI, respectively. Then, mitochondria 
extraction was performed as previously described [35]. In brief, cells were harvested, resuspended in 
isolation buffer for cells (IBC, containing 200 mM sucrose, 10 mM Tris/MOPS, 1 mM EDTA/Tris, pH 
7.4), and homogenized by a glass potter homogenizer. Nuclei and unbroken cells were removed by 
centrifugation (600× g for 10 min). Supernatants were centrifuged for 30 min at 10,000× g, obtaining 
upper cytosolic fractions and mitochondrial pellets; the latter were resuspended in RIPA buffer (PBS 
pH 7.4, 1% NP-40, 0.5% sodium deoxycholate, and 0.1% sodium dodecyl sulfate) containing a 
protease and phosphatase inhibitor cocktail (Sigma-Aldrich, Milan, Italy). Protein concentration was 
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determined using Bio-Rad Protein Assay (Bio-Rad Laboratories, Hercules, CA, USA) and Western 
blotting was performed as next described. 
2.6. Western Blot Analysis 
Western blot analysis was conducted basically as previously reported [36]. In detail, MCF-7 and 
HeLa cells were grown to 70–80% confluence, added to DMSO, or treated with 15 and 30 µM OI, 
respectively, for 24 h. In order to obtain total cell lysates, harvested cells were lysed using 200 µL of 
lysis buffer as previously reported. Cytosolic and mitochondrial fractions were isolated as already 
described. Identical amounts of proteins from total lysate, mitochondrial, or cytosolic fraction were 
resolved on SDS-polyacrylamide gel, blotted to nitrocellulose membrane, and probed with proper 
primary antibodies (Santa Cruz Biotechnology, Dallas, TX, USA) [37]. Immunoreactive products were 
identified by using ECL Western blotting detection system (Bio-Rad Laboratories, Hercules, CA, 
USA) [38]. 
2.7. Mitochondrial Staining 
Mitochondrial activity was assessed using MitoTracker Orange (Invitrogen, Milan, Italy), a 
fluorescent dye that enters mitochondria in a membrane potential-dependent way. Mitochondrial 
mass was determined using MitoTracker Deep-Red (Invitrogen, Milan, Italy), a far red-fluorescent 
dye that is largely used to label mitochondria. Both MCF-7 and HeLa cells were treated using 15 and 
30 µM OI, respectively, for 24 h. Control cells were added with DMSO and simultaneously processed 
[39]. Then, cells were incubated in the dark for 30–60 min at 37 °C with pre-warmed MitoTracker 
staining solution (diluted in PBS/CM to reach a final concentration of 10 nM). All the next steps were 
still carried out in the dark. Cells were rinsed in PBS, harvested, and re-suspended in 300 µL of 
PBS/CM. Cells were then examined by flow cytometry using Fortessa (BD Bioscience, San Jose, CA, 
USA). Data analysis was performed using FlowJo software (Tree Star Inc., Ashland, OR, USA). 
2.8. ROS Production 
Intracellular level of reactive oxygen species (ROS) was assessed by using CM-H2DCFDA 
(C6827, Invitrogen, Milan, Italy), a cell-permeable fluorogenic probe, which is deacetylated by 
intracellular esterases and can be oxidized in the presence of intracellular ROS, becoming highly 
fluorescent [35]. MCF-7 and HeLa cells were seeded into 96-well tissue culture plates at a density of 
5 × 104 cells/well and treated with 15 and 30 µM OI, respectively, for 24 h. Control cells were added 
with DMSO and processed at the same time. Then, cells were washed with PBS and stained in the 
dark with CM-H2DCFDA (diluted in PBS/CM to a final concentration of 1 µM) for 20 min at 37 °C. 
Next steps were also performed in the dark, in order to avoid probe oxidation. Cells were washed 
three times with PBS, harvested, re-suspended in PBS/CM, and fluorescence was measured by using 
Fortessa (BD Bioscience, San Jose, CA, USA). ROS levels were estimated by using mean fluorescent 
intensity of the viable cell population. Results were analyzed by the use of FlowJo software (Tree Star 
Inc., Ashland, OR, USA). 
2.9. Tunel Assay 
Apoptosis was tested by enzymatic labeling of DNA strand breaks using terminal 
deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick end-labeling (TUNEL) assay, 
following the guidelines of the manufacturer (TUNEL assay kit, Promega, Madison, WI, USA). 
Briefly, MCF-7 and HeLa cells were added with DMSO or treated with 15 and 30 µM OI, respectively, 
for 72 h. MCF-10A were added to DMSO or treated using 30 µM OI, for 72 h. Next, nuclear staining 
was achieved using 0.2 mg/mL 4′,6- diamidino-2-phenylindole (DAPI, Sigma-Aldrich, Milan, Italy) 
[40] and samples were examined using a fluorescent microscope (Olympus BX4 equipped with 
CSV1.14 software employing a CAMXC-30 for image acquisition). Images were representative of 
three independent experiments. 
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2.10. Statistical Analysis 
Data represented means ± standard deviation (SD) considering at least three independent 
experiments, with ≥ three technical replicates per experiment, except when otherwise stated. 
Statistical significance was evaluated using analysis of variance (ANOVA) test by GraphPad Prism 7 
(GraphPad Inc., San Diego, CA, USA). Dunnett’s test was employed as a post hoc test for pairwise 
comparisons. All statistical tests were two-sided, and p ≤ 0.05 was considered significant. 
3. Results 
3.1. Antiproliferative Activity 
The effects on cancer cell proliferation of the aforementioned compounds were evaluated in two 
human tumor cell lines, MCF-7 and HeLa, by using the (3-(4,5- dimethylthiazol-2-yl)-2,5-diphenyl 
tetrazolium bromide) MTT assay. For this purpose, both cell lines were treated with increasing doses 
(1, 10, 50, 75, and 100 µM) of different oxazolidin-2-one derivatives (OA–OI) for 72 h (data not 
shown). Cells were also exposed to doxorubicin (DOX), in order to compare antiproliferative effects 
of such derivatives to those of this extensively employed anti-cancer drug. Among all the tested 
compounds, we found that only 2-oxazolidinones OA, OB, OC, and OI displayed an interesting 
anti-proliferative activity (Figure 1a,b). 
In particular, OI treatment elicited the highest effect by reducing cell viability in a dose-
dependent manner (Figure 1a,b) both in MCF-7 and HeLa cells, with half-maximal inhibitory 
concentration (IC50) values equal to 17.66 and 31.10 µM, respectively (Table 1). 
Table 1. Cytotoxic activity of 5-(Carbamoylmethylene)-oxazolidin-2-ones in comparison to that of 
doxorubicin a. 
Compound HeLa MCF-7 MCF-10A 
 IC50 95% Confidence interval IC50 95% Confidence interval IC50 95% Confidence interval 
DOX 3.61 3.02 to 4.32 4.04 3.25 to 5.03 31.75 25.16 to 40.08 
OA 52.53 42.81 to 64.45 56.90 50.43 to 69.18 414.3 336.3 to 510.5 
OB 98.21 81.46 to 118,0 121.8 107.0 to 139.7 469.6 378.9 to 582.1 
OC 99.47 88.42 to 111.9 163.3 135.2 to197.2 494.5 406.2 to 602.2 
OD 154.5 136.4 to 175.1 338.4 284.8 to 402.0 506.4 410.1 to 625.4 
OE 129.3 114.0 to 146.0 303.7 258.3 to 357.0 978.2 718.3 to 1332 
OF 159.4 138.5 to 183.6 409.3 348.8 to 480.3 718.4 506.6 to 1019 
OG 134.4 113.5 to 159.2 344.9 290.4 409.6 677.1 530.3 to 864.5 
OH 54.21 42.67 to 68.88 92.91 78.99 to 109.3 318.8 263.1 to 386.3 
OI 31.10 26.29 to36.80 17.66 15.67 to 19.91 351.3 288.4 to 427.8 
a Data are presented as IC50 values (µM) and 95% confidence intervals obtained by nonlinear 
regression analysis of three independent experiments. 
On the other hand, the compounds OA, OB, and OC revealed noticeable inhibitory activity 
either on MCF-7 or on HeLa cell growth only when they were used at high concentrations 
(ranging between 50 and 100 µM). It should be underlined that, although OI was less active than 
DOX, as highlighted by its higher IC50 values (Table 1), OI treatment up to 72 h induced no 
significant anti-proliferative effect on non-tumorigenic MCF-10A breast epithelial cells (Figure 
1c, Table 1). These findings highlighted that OI had a more specific inhibitory effect on cancer 
cells with respect to that exerted on non-tumorigenic cells. 
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Figure 1. Effects of the compounds OA-OI on MCF-7, HeLa, and MCF-10A cell growth. (a) Breast 
cancer cells (MCF-7), (b) human uterine cervix adenocarcinoma cells (HeLa), and (c) non-tumorigenic 
breast epithelial cells (MCF-10A) were treated for 72 h with vehicle alone (control cells, CTRL) or 
increasing doses (1 to 100 µM) of each compounds or doxorubicin (DOX), as indicated. Cell viability 
was assessed by MTT assay and was expressed as percentage of growth vs. CTRL. Values represent 
means ± SD of three different experiments, each performed with triplicate samples. * p value 
< 0.05; ** p value < 0.01; *** p value < 0.001. 
3.2. Oxazolidinone OI Induces Cell Cycle Arrest 
In order to understand whether OI antiproliferative effect could be a consequence of cell cycle 
perturbations, we assessed flow cytometric cell cycle analysis and estimated the deployment of cells 
within the three main phases of the cell cycle, by propidium iodide (PI) staining. Both MCF-7 and 
HeLa cell lines were treated for 24 h with the vehicle alone (DMSO) or with the compound OI used 
at 15 and 30 µM, respectively. 
Our results revealed that this treatment arrested cells in the G0/G1-phase of the cell cycle (Figure 
2a), in agreement with the OI induced antiproliferative effect shown in Figure 1. 
In particular, after 24 h, we observed a significant increase of the percentage of MCF-7 cells in 
the G0/G1 phase (15%), concomitant with a reduction of the fraction of cells in the S-phase (30%). 
Similar results were observed in HeLa cells (Figure 2a) since OI treatment induced a considerable 
decrease of cells in the S phase, together with a remarkable increase in the G1 phase. Conversely, we 
did not evidence any noticeable effect on the cell cycle in MCF-10A non-tumorigenic breast epithelial 
cells (Figure S1a), indicating that OI selectively inhibits cancer cell proliferation by induction of 
G0/G1 cell cycle arrest. 
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Figure 2. Effects of the compound OI on the cell cycle progression in cancer cells. (a) Quantitative 
analysis of the percentage of cells arrested in different phases of the cell cycle was indicated. 
Immunoblot and densitometric analyses of several controlling proteins of the G1/S phase transition 
in MCF-7 (b) and HeLa (c,d) treated cells. GAPDH was used as a loading control. Histograms 
represent means ± SD of three different experiments in which band intensities were assessed as optical 
density arbitrary units (OD), and expressed as fold change vs. control samples (CTRL). It is 
noteworthy that OI treatment impairs the G1/S transition of both cancer cell lines. * p value < 0.05; ** 
p value < 0.01; *** p value < 0.001; **** p value < 0.0001. 
In order to confirm our findings, we investigated possible changes in the expression levels of 
proteins involved in the cell cycle regulation, including cyclin D1, CDK4, and phosphorylated 
retinoblastoma tumor suppressor (pRb) protein. MCF-7 cells were treated with OI, used at 15 µM for 
24 and 72 h, and whole cell lysates were subjected to immunoblotting analysis. Consistently with the 
observed G1/S transition arrest of the cell cycle, this treatment significantly reduced cyclin D1 and 
phosphorylated Rb protein content in a time dependent manner, whereas CDK4 protein expression 
levels remained unaffected (Figure 2b,c). Similar results were also observed on 30 µM OI-treated 
HeLa cells, under the same experimental conditions (Figure 2b,d). These data suggest that OI 
treatment arrest cells in the G1-S phase of the cell cycle by inhibiting cyclin D1 expression and Rb 
phosphorylation. In addition, both these events were not dependent on cell type. 
3.3. OI Triggers Apoptotic Cell Death in MCF-7 and HeLa cells 
Since several reports evidenced that oxazolidinones were able to induce apoptosis [18,23,24], we 
next tested whether also OI exposure could induce cell death by triggering apoptosis, in both our 
tested cell lines. The impact of this oxazolidin-2-one derivative on apoptosis was assessed by using 
two different approaches. Firstly, TUNEL assay was performed in order to test OI ability to induce 
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DNA fragmentation, which is a late event of apoptosis. Hence, MCF-7 and HeLa cells were incubated 
for 72 h with 15 or 30 µM OI, respectively, prior to analysis. MCF-10A cells were incubated for 72 h 
with 30 µM OI, the highest concentration used for cancer cells, prior to analysis. Our results 
evidenced an increased number of TUNEL-positive cells (Figure 3a,b). In control cells (cells treated 
with DMSO; CTRL), apoptotic population was 2.3% in MCF-7 and 10% in HeLa cells; after the 
treatment, the apoptotic rate reached 34.3% and 53.2% in MCF-7 and HeLa cells, respectively (Figure 
3a). Conversely, we did not evidence any noticeable effect on MCF-10A, non-tumorigenic breast 
epithelial cells (Figure S1b). 
 
Figure 3. OI treatment triggers cell death by apoptosis. (a) TdT-mediated dUTP nick-end-labeling 
(TUNEL) assay in MCF-7 and HeLa cells treated for 72 h with DMSO (CTRL) or 15 and 30 µM OI, 
respectively. DAPI was used to visualize the cell nucleus. Scale Bars 50 µm. Histograms represent 
means ± SD of apoptotic cells from three independent experiments. (b) Immunoblot analysis of pro-
caspases 8 and 9 after 24 and 72 h of OI treatment (see Materials and Methods, par. 2.6). GAPDH was 
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used as a loading control. Densitometric quantification of pro-caspase expression levels in MCF-7 (c) 
and HeLa (d) treated cells vs. control cells. Remarkably, OI treatment induces apoptosis by activating 
the intrinsic caspase-dependent apoptotic pathways. Values are means ± SD of three different 
experiments. *** p value < 0.001; **** p value < 0.0001. 
Secondly, apoptosis onset was investigated by testing the activation of caspases -8 and -9, which 
are two well-known biochemical markers of programmed cell death. For this purpose, MCF-7 and 
HeLa cells were treated with 15 or 30 µM OI, respectively, both for 24 and 72 h, and expression levels 
of procaspases -8 and -9 were assessed by Western blot analysis (Figure 3b). Our results showed that 
OI treatment time-dependently activated proteolytic cleavage of inactive pro-caspase-9 into its active 
form, whereas expression level of activated caspase-8 was unaffected (Figure 3b–d). Since the 
extrinsic apoptotic pathway includes caspase-8 activation, while caspase-9 is involved in the intrinsic 
mitochondria pathway [30], our findings prompted us to hypothesize that OI compound could 
activate the mitochondrial caspase-dependent apoptotic pathway, in both MCF-7 and HeLa cells. 
3.4. OI Reduces Mitochondrial Membrane Potential with a Significant Increase in ROS Levels 
In order to validate that OI treatment was able to trigger apoptosis cell death by activating the 
intrinsic mitochondrial pathway, we tested if this compound could induce mitochondrial damage. 
To this end, we investigated OI ability to induce a loss of mitochondrial membrane potential leading 
to alterations in mitochondrial permeability, which resulted in the release of cytochrome c from the 
mitochondria (where it is habitually located) into the cytosol. Remarkably, this latter event represents 
a hallmark of the apoptotic process [41]. Hence, both MCF-7 and HeLa cells were treated for 24 h 
with 15 or 30 µM OI, respectively, stained with specific metabolic probes, and analyzed by 
fluorescence-activated cell sorting (FACS). Our results showed that OI treatment was able to decrease 
mitochondrial membrane potential as evaluated using MitoTracker Orange (Figure 4a), as well as 
mitochondrial mass, as demonstrated by MitoTracker Deep-Red. (Figure 4a). The ratio of 
mitochondrial membrane potential (MitoTracker Orange) vs. mitochondrial mass (MitoTracker 
Deep-Red) was also calculated, showing that OI treatment significantly decreased mitochondrial 
membrane potential per mitochondria (Figure 4a) in MCF-7 as well as in HeLa cells (Figure 4a). 
Additionally, Western blotting analysis performed on the lysates of cells treated under the same 
experimental conditions confirmed cytochrome c release. Indeed, significant increases in cytochrome 
c levels in the cytosolic fraction, together with concomitant decreases in its mitochondrial levels, were 
found in both MCF-7 (Figure 4b,c) and HeLa (Figure 4b,d) OI-treated cells, when compared to the 
control cells. 
It is known that reactive oxygen species (ROS) are referred as being mediators of apoptosis, 
particularly due to their great reactivity towards various macromolecules involved in the 
electrochemical mitochondrial membrane balance [42], [43]. On this basis, we investigated whether 
ROS production could underlie OI-induced apoptosis (Figure 5a,b). 
Both MCF-7 and HeLa cells were treated for 24 h with 15 and 30 µM OI, respectively, alone or 
in the presence of a ROS quencher such as N-acetyl-l-cysteine (NAC). Then, ROS levels were 
evaluated by FACS analysis using the CM-H2DCFDA probe. We found that this treatment 
significantly stimulated ROS generation in both the tested cell lines, when compared to the control 
cells (Figure 5a,b). Furthermore, the observed increases were no longer evident in the presence of 
NAC (Figure 5a,b). Finally, we proved that the anti-proliferative activity evidenced after OI exposure 
was strictly dependent on ROS generation, as highlighted by the increased cell viability found in both 
cell types in the presence of NAC (Figure 5c,d). Indeed, MCF-7 and HeLa cells exhibited resistance 
to OI when co-incubated for 72 h with 3 mM NAC, showing 40% (Figure 5c) and 35% (Figure 5d) 
recovery in growth, respectively. These last data supported our hypothesis, according to which ROS 
production could underlay mitochondrial damage, cytotoxicity, and cell death induced by the 
compound OI. 
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Figure 4. OI treatment induces mitochondrial damage in cancer cells. (a) Both MCF-7 and HeLa cells 
were treated for 24 h either with DMSO (CTLR) or 15 and 30 µM OI, respectively, then they were 
stained with different metabolic probes and analyzed by FACS. Note that the treatment decreases 
mitochondrial mass (MitoTracker Deep-Red) and mitochondrial membrane potential (MitoTracker 
Orange). Assessment of mitochondrial membrane potential vs. mitochondrial mass displayed that OI 
decreases mitochondrial membrane potential per mitochondria. Immunoblot and densitometric 
analysis of cytochrome c in treated MCF-7 (b,c) and HeLa (b,d) cells. GAPDH was used as a loading 
control of cytosolic fractions, whereas COX4 of the mitochondrial one. A significant release of 
cytochrome c into the cytosol is revealed in both tested cancer cell lines. Histograms represent means 
± SD of three independent experiments in which band intensities were assessed as optical density 
arbitrary units (OD) and expressed as fold change vs. control samples (CTRL). **** p value < 0.0001. 
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Figure 5. The compound OI causes a significant increase in ROS levels. Both MCF-7 (a) and HeLa 
(b) cells were treated for 24 h with 15 and 30 µM OI, respectively, alone and/or in the presence 
of N-acetyl-l-cysteine (NAC); ROS levels were evaluated by FACS analysis using the CM-
H2DCFDA probe. Cell proliferation assay (MTT assay) was performed in both treated MCF-7 (c) 
and HeLa (d) cells, in the presence or absence of 3 mM NAC. Note that after 72 h, in the presence 
of NAC, cells displayed recovery in growth. Values represent means ± SD of three different 
experiments, each performed with triplicate samples. * p value < 0.05; **** p value < 0.0001. 
4. Discussion 
Despite the fact that glycolysis has long been believed to be a key metabolic pathway for anabolic 
growth and energy production in cancer cells, it is currently evident that mitochondria play a critical 
role in oncogenesis by affecting all its steps [44]. Mitochondria are involved in bioenergetic 
metabolism, as well as providing specific metabolites that support oncogenesis [45]. Several 
mitochondrial metabolic pathways may adjust in order to modulate anabolic or bioenergetic 
functions, thus conferring a great metabolic plasticity to tumor cells [46,47]. These organelles supply 
pivotal components for redox control and participate in transcriptional regulation; moreover, 
mitochondrial membranes permeabilization represents a crucial step in the programmed cell death 
[48–51]. Remarkably, mitochondrial function proved to be essential for an effective formation and 
propagation of CSCs [52], which are a sub-population of cancer cells responsible for initiation, 
development, and cancer recurrence; furthermore, they are usually resistant to conventional radio- 
and chemotherapy [53–57]. In this light, recently, different researches have been focused on 
developing several molecules endowed with antineoplastic properties and able to target 
mitochondria, in order to find new future anticancer candidates [58–60]. 
Here, we proved the ability of the synthetic 5-(carbamoylmethylene)-oxazolidin-2-one 
derivatives (OA–OI) to induce antiproliferative activity in two different cancer cell lines, MCF-7 and 
HeLa cells, without affecting the proliferation of the non-tumorigenic MCF-10A cells. Among the 
tested compounds, only OA, OB, OC, and OI displayed an interesting anti-proliferative activity. 
Remarkably, OI emerged as the most promising anticancer agent, since it showed the lowest IC50 
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value in both the tested cancer cell lines. OI treatment was also associated with apoptosis induction, 
which was triggered by increased ROS levels and mitochondrial damage. 
Cell cycle alterations leading to abnormal cell proliferation represent a common cancer feature 
[61]. Therefore, a promising anticancer agent should be able to target regulatory elements of the cell 
cycle in order to block it, so preventing tumor proliferation. Cyclins and CDKs exert a critical function 
in regulating the cell cycle progression [62]. In detail, Cyclins D plays a key role in the transition from 
the G1 to the S phase, and the G1 progression requires cyclin D1-CDK4/6 complex formation [63]. 
Additionally, activated cyclin/CDK complexes phosphorylate the retinoblastoma (Rb) tumor 
suppressor protein, which promotes the cell cycle transition from the G1 to the S phase [64]. By using 
cytofluorimetric and immuno-detection analyses, we proved that OI treatment was associated with 
an impaired cell cycle progression. In detail, we observed a cell cycle arrest in the G1 phase together 
with a reduced percentage of cells in the S phase, in a time dependent manner. At the same time, we 
found concomitant decreased expression levels of both cyclin D1 and phosphorylated Rb protein. 
Scientific literature data reported that different oxazolidin-2-one derivatives could inhibit cell 
proliferation and promote apoptosis in a variety of cancer cell lines [18,23,24]. On this basis, we 
explored OI ability to induce apoptosis in MCF-7 and HeLa cells. Our findings proved that this 
compound was able to trigger apoptosis, as highlighted by a significant increase in the percentage of 
TUNEL-positive cells and by a concomitant decrease in procaspase-9 levels observed in both cell 
lines, when compared to the control cells. Conversely, procaspase-8 expression levels were 
unaffected. 
Thus, our findings support the hypothesis that OI treatment is able to inhibit cell cycle 
progression and to trigger the intrinsic apoptotic mechanism through the activation of procaspase-9 
in initiator caspase-9, which is involved only in this apoptotic pathway [65]. Accordingly, we found 
no decrease in procaspase-8 protein levels, proving a failed activation of the initiator caspase-8, 
highlighting that the extrinsic apoptotic pathways is not implicated in cell death [65]. Moreover, in 
good agreement with our hypothesis, we detected, by Western blot analysis, a noticeable increase in 
cytochrome c release from mitochondria into the cytosol, which is a key event in the caspase-
dependent mitochondrial pathway. Indeed, within the cytosol, cytochrome c binds to apoptotic 
protease-activating factor-1 (Apaf-1) producing the apoptosome complex. The latter recruits and 
activates the initiator procaspase-9, which in turn induces cleavage/activation of the downstream 
effector caspases-3 and -7 [43]. Mitochondria-to-cytosol translocation of cytochrome c is caused by a 
mitochondrial damage due to a loss of mitochondrial membrane potential, followed by 
mitochondrial membrane permeabilization [66]. In this context, our results clearly demonstrated that 
OI treatment significantly reduced mitochondrial membrane potential, confirming its ability to 
produce mitochondrial damage, as well as to trigger cell death by activating the intrinsic apoptotic 
pathway. 
Mitochondrial dysfunction was also confirmed by a decrease in the mitochondrial mass detected 
after OI treatment. In this regard, it is known that mitochondrial mass affects mitochondrial function, 
and it depends on turnover and biogenesis, two metabolic processes acting as tumorigenesis 
regulators [67]. Reactive oxygen species (ROS) are generated by several metabolic pathways, and 
their role is determined by their concentration. At physiologically low levels, they act as “redox 
messengers” in intracellular regulation, whereas their overproduction can induce cell death [43]. 
Moreover, ROS are considered mediators of apoptosis, mainly because of their involvement in 
mitochondrial outer membrane permeabilization and in the translocation of pro-apoptotic 
mitochondrial proteins into the cytosol [42,43]. As a consequence, we investigated whether OI could 
induce an increase in ROS levels, which in turn could trigger apoptotic cell death. Our outcomes 
demonstrated that OI treatment increased overall ROS production. Noteworthily, we found 
increased cell viability when this treatment was performed in the presence of NAC, suggesting that 
high ROS levels, together with mitochondrial damage and cell death, could be responsible for OI 
anti-proliferative activity. 
Taken together, our findings highlight that the tested oxazolidin-2-one derivative induce cell 
death through the activation of the intrinsic mitochondrial pathway in MCF-7 and HeLa cells, 
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without exerting any effects on non-tumorigenic MCF-10A breast epithelial cells. In conclusion, the 
compound OI might represent a promising drug candidate for future therapies in cancer treatment, 
as well as the fact that it can be considered a very promising starting point for future chemical 
syntheses in order to find new molecules endowed with potential anticancer properties. 
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